Trade Viridian Therapeutics, Inc. - VRDN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.11 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 22.01 |
| Open | 22.69 |
| 1-Year Change | 29.88% |
| Day's Range | 21.06 - 23.58 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 13, 2024 | 22.01 | 0.97 | 4.61% | 21.04 | 22.34 | 21.04 |
| Sep 12, 2024 | 20.66 | 0.97 | 4.93% | 19.69 | 22.21 | 19.58 |
| Sep 11, 2024 | 19.75 | 1.24 | 6.70% | 18.51 | 20.59 | 17.70 |
| Sep 10, 2024 | 18.69 | 2.53 | 15.66% | 16.16 | 18.94 | 15.09 |
| Sep 9, 2024 | 14.15 | 0.20 | 1.43% | 13.95 | 15.03 | 13.75 |
| Sep 6, 2024 | 14.05 | 0.65 | 4.85% | 13.40 | 14.29 | 13.32 |
| Sep 5, 2024 | 13.45 | -1.40 | -9.43% | 14.85 | 14.92 | 13.16 |
| Sep 4, 2024 | 14.81 | 0.77 | 5.48% | 14.04 | 15.07 | 14.04 |
| Sep 3, 2024 | 14.47 | 0.00 | 0.00% | 14.47 | 15.40 | 14.13 |
| Aug 30, 2024 | 14.63 | -0.29 | -1.94% | 14.92 | 15.05 | 14.61 |
| Aug 29, 2024 | 14.96 | 0.00 | 0.00% | 14.96 | 15.53 | 14.80 |
| Aug 28, 2024 | 14.84 | 0.07 | 0.47% | 14.77 | 15.21 | 14.67 |
| Aug 27, 2024 | 14.94 | 0.17 | 1.15% | 14.77 | 15.23 | 14.51 |
| Aug 26, 2024 | 15.12 | -0.06 | -0.40% | 15.18 | 15.50 | 14.86 |
| Aug 23, 2024 | 15.01 | -0.32 | -2.09% | 15.33 | 15.61 | 14.98 |
| Aug 22, 2024 | 15.31 | -0.24 | -1.54% | 15.55 | 15.55 | 14.97 |
| Aug 21, 2024 | 15.54 | -0.06 | -0.38% | 15.60 | 16.00 | 15.27 |
| Aug 20, 2024 | 15.66 | 0.11 | 0.71% | 15.55 | 15.93 | 15.37 |
| Aug 19, 2024 | 15.78 | 0.55 | 3.61% | 15.23 | 15.80 | 15.18 |
| Aug 16, 2024 | 15.45 | 0.87 | 5.97% | 14.58 | 15.90 | 14.58 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Viridian Therapeutics, Inc. Company profile
About Viridian Therapeutics Inc
Viridian Therapeutics, Inc. (Viridian) is a biotechnology company that is focused on advancing treatments for patients suffering from serious diseases. The Company’s products include VRDN-001 and VRDN-002. The Company’s advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R). The IGF-1R is a clinically and commercially validated target for the treatment of thyroid eye disease (TED). TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. The Company’s product candidate, VRDN-002, is a distinct anti-IGF-1R antibody that incorporates half-life extension technology. The VRDN-002 is designed to support the administration as a convenient, low-volume, subcutaneous injection.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Viridian Therapeutics Inc revenues increased from $1.1M to $3M. Net loss decreased 28% to $79.4M. Revenues reflect Collaboration revenue increase from $735K to $3M. Lower net loss reflects Acquired in-process research and develop decrease from $69.9M (expense) to $0K, Interest and other expense decrease of 99% to $3K (expense), Interest and other income increase of 84% to $318K (income).
| Industry: | Biotechnology & Medical Research (NEC) |
221 Crescent Street
Bldg. 17, Suite 401
WALTHAM
MASSACHUSETTS 02453
US
News
FOMC Decision Preview
As the US Federal Reserve prepares for its most significant decision since ending the rate hike cycle in mid-2023, the balance of risks has shifted. With inflation stabilizing at 2.6% and rising unemployment at 4.2%, the FOMC faces increasing pressure to address employment concerns. Markets anticipate a rate cut, with debate on the extent of the reduction.
09:48, 16 September 2024
ECB Preview: cuts expected but the pace is uncertain
Markets expect the ECB to cut rates again in September, but how many more?
12:34, 11 September 2024
Market analysis: US CPI and PPI
Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.
07:56, 10 September 2024
Introducing Newsquawk: your new in-platform newsfeed
We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.
14:09, 20 August 2024
Jackson Hole Preview: All eyes on Powell and Gold
The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.
15:24, 19 August 2024
All eyes on inflation: US and UK CPI take centre stage
Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.
14:41, 13 August 2024
European stocks face resistance in their attempt to recover
European stocks struggle to recover as the tech sector faces continued downside pressure in Asia.
13:56, 9 August 2024People also watch
Still looking for a broker you can trust?
Join the 640,000+ traders worldwide that chose to trade with Capital.com